WO2023230770A1 - Methods of lung adenocarcinoma treatment with non anti-luad drugs or compounds - Google Patents
Methods of lung adenocarcinoma treatment with non anti-luad drugs or compounds Download PDFInfo
- Publication number
- WO2023230770A1 WO2023230770A1 PCT/CN2022/096011 CN2022096011W WO2023230770A1 WO 2023230770 A1 WO2023230770 A1 WO 2023230770A1 CN 2022096011 W CN2022096011 W CN 2022096011W WO 2023230770 A1 WO2023230770 A1 WO 2023230770A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- luad
- drug
- drugs
- compounds
- clinical
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 55
- 239000003814 drug Substances 0.000 title claims abstract description 55
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 title claims abstract description 38
- 201000005249 lung adenocarcinoma Diseases 0.000 title claims abstract description 38
- 150000001875 compounds Chemical class 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims abstract description 16
- 238000011282 treatment Methods 0.000 title claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 10
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 10
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 6
- ZLHZLMOSPGACSZ-NSHDSACASA-N (6s)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound O([C@H]1CN2C=C(N=C2OC1)[N+](=O)[O-])CC1=CC=C(OC(F)(F)F)C=C1 ZLHZLMOSPGACSZ-NSHDSACASA-N 0.000 claims description 5
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 claims description 5
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims description 5
- LJOQGZACKSYWCH-LHHVKLHASA-N (s)-[(2r,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol Chemical compound C1=C(OC)C=C2C([C@H](O)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 LJOQGZACKSYWCH-LHHVKLHASA-N 0.000 claims description 5
- HQFWVSGBVLEQGA-UHFFFAOYSA-N 4-aminobenzoic acid 3-(dibutylamino)propyl ester Chemical compound CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1 HQFWVSGBVLEQGA-UHFFFAOYSA-N 0.000 claims description 5
- LREQLEBVOXIEOM-UHFFFAOYSA-N 6-amino-2-methyl-2-heptanol Chemical compound CC(N)CCCC(C)(C)O LREQLEBVOXIEOM-UHFFFAOYSA-N 0.000 claims description 5
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 5
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 5
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 claims description 5
- LJOQGZACKSYWCH-AFHBHXEDSA-N Hydroquinidine Natural products C1=C(OC)C=C2C([C@@H](O)[C@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 LJOQGZACKSYWCH-AFHBHXEDSA-N 0.000 claims description 5
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 5
- 229930010555 Inosine Natural products 0.000 claims description 5
- XAGMUUZPGZWTRP-ZETCQYMHSA-N LSM-5745 Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1C1(N)CC1 XAGMUUZPGZWTRP-ZETCQYMHSA-N 0.000 claims description 5
- FNQQBFNIYODEMB-UHFFFAOYSA-N Meticrane Chemical compound C1CCS(=O)(=O)C2=C1C=C(C)C(S(N)(=O)=O)=C2 FNQQBFNIYODEMB-UHFFFAOYSA-N 0.000 claims description 5
- IDCHQQSVJAAUQQ-UHFFFAOYSA-N N,N-diethyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethanamine Chemical compound O1C(CCN(CC)CC)=NC(C=2C=CC=CC=2)=N1 IDCHQQSVJAAUQQ-UHFFFAOYSA-N 0.000 claims description 5
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 claims description 5
- BRZANEXCSZCZCI-UHFFFAOYSA-N Nifenazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C)C(C)=C1NC(=O)C1=CC=CN=C1 BRZANEXCSZCZCI-UHFFFAOYSA-N 0.000 claims description 5
- 239000005480 Olmesartan Substances 0.000 claims description 5
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 5
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 claims description 5
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 5
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 5
- 239000004012 Tofacitinib Substances 0.000 claims description 5
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 5
- 229960004373 acetylcholine Drugs 0.000 claims description 5
- OBDOVFRMEYHSQB-UHFFFAOYSA-N almitrine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C=2N=C(NCC=C)N=C(NCC=C)N=2)CC1 OBDOVFRMEYHSQB-UHFFFAOYSA-N 0.000 claims description 5
- 229960005039 almitrine Drugs 0.000 claims description 5
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 claims description 5
- 229960001667 alogliptin Drugs 0.000 claims description 5
- SVEBYYWCXTVYCR-LBPRGKRZSA-N alpha-methyl-L-dopa ethyl ester Chemical compound CCOC(=O)[C@@](C)(N)CC1=CC=C(O)C(O)=C1 SVEBYYWCXTVYCR-LBPRGKRZSA-N 0.000 claims description 5
- 229960002684 aminocaproic acid Drugs 0.000 claims description 5
- LDXYBEHACFJIEL-HNNXBMFYSA-N anagliptin Chemical compound C=1N2N=C(C)C=C2N=CC=1C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N LDXYBEHACFJIEL-HNNXBMFYSA-N 0.000 claims description 5
- 229950009977 anagliptin Drugs 0.000 claims description 5
- XRCFXMGQEVUZFC-UHFFFAOYSA-N anisindione Chemical compound C1=CC(OC)=CC=C1C1C(=O)C2=CC=CC=C2C1=O XRCFXMGQEVUZFC-UHFFFAOYSA-N 0.000 claims description 5
- 229960002138 anisindione Drugs 0.000 claims description 5
- NZLBHDRPUJLHCE-UHFFFAOYSA-N aprindine Chemical compound C1C2=CC=CC=C2CC1N(CCCN(CC)CC)C1=CC=CC=C1 NZLBHDRPUJLHCE-UHFFFAOYSA-N 0.000 claims description 5
- 229960004957 aprindine Drugs 0.000 claims description 5
- IIOPLILENRZKRV-UHFFFAOYSA-N azosemide Chemical compound C=1C=CSC=1CNC=1C=C(Cl)C(S(=O)(=O)N)=CC=1C1=NN=N[N]1 IIOPLILENRZKRV-UHFFFAOYSA-N 0.000 claims description 5
- 229960004988 azosemide Drugs 0.000 claims description 5
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 claims description 5
- 229960000517 boceprevir Drugs 0.000 claims description 5
- AAQOQKQBGPPFNS-UHFFFAOYSA-N bretylium Chemical compound CC[N+](C)(C)CC1=CC=CC=C1Br AAQOQKQBGPPFNS-UHFFFAOYSA-N 0.000 claims description 5
- 229960002624 bretylium tosilate Drugs 0.000 claims description 5
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 claims description 5
- 229960005263 bucladesine Drugs 0.000 claims description 5
- 229960003369 butacaine Drugs 0.000 claims description 5
- 229960000530 carbenoxolone Drugs 0.000 claims description 5
- OBZHEBDUNPOCJG-SZTGPWMUSA-N carbenoxolone Chemical compound C([C@H]1C2=CC(=O)[C@@H]34)[C@](C)(C(O)=O)CC[C@@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@H]1[C@@]3(C)CC[C@@H](OC(=O)CCC(O)=O)C1(C)C OBZHEBDUNPOCJG-SZTGPWMUSA-N 0.000 claims description 5
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 claims description 5
- 229960000603 cefalotin Drugs 0.000 claims description 5
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims description 5
- 229960002023 chloroprocaine Drugs 0.000 claims description 5
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 5
- 229960002173 citrulline Drugs 0.000 claims description 5
- OBATZBGFDSVCJD-UHFFFAOYSA-N de-O-acetyl-lanatoside C Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)C(O)C4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(O)C1OC1OC(CO)C(O)C(O)C1O OBATZBGFDSVCJD-UHFFFAOYSA-N 0.000 claims description 5
- OBATZBGFDSVCJD-LALPQLPRSA-N deslanoside Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OBATZBGFDSVCJD-LALPQLPRSA-N 0.000 claims description 5
- 229960001324 deslanoside Drugs 0.000 claims description 5
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 claims description 5
- 229960001912 dicoumarol Drugs 0.000 claims description 5
- OWQUZNMMYNAXSL-UHFFFAOYSA-N diphenylpyraline Chemical compound C1CN(C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 OWQUZNMMYNAXSL-UHFFFAOYSA-N 0.000 claims description 5
- 229960000879 diphenylpyraline Drugs 0.000 claims description 5
- 238000002474 experimental method Methods 0.000 claims description 5
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 claims description 5
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 claims description 5
- 229960000326 flunarizine Drugs 0.000 claims description 5
- RIKMMFOAQPJVMX-UHFFFAOYSA-N fomepizole Chemical compound CC=1C=NNC=1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 claims description 5
- 229960004285 fomepizole Drugs 0.000 claims description 5
- 229960000457 gallopamil Drugs 0.000 claims description 5
- NJDRXTDGYFKORP-LLVKDONJSA-N garenoxacin Chemical compound N([C@@H](C1=CC=2)C)CC1=CC=2C(C=1OC(F)F)=CC=C(C(C(C(O)=O)=C2)=O)C=1N2C1CC1 NJDRXTDGYFKORP-LLVKDONJSA-N 0.000 claims description 5
- 229960001430 garenoxacin Drugs 0.000 claims description 5
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 claims description 5
- 229960003602 guanethidine Drugs 0.000 claims description 5
- 229960005402 heptaminol Drugs 0.000 claims description 5
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 claims description 5
- 229960003313 hydroflumethiazide Drugs 0.000 claims description 5
- 229960000811 hydroquinidine Drugs 0.000 claims description 5
- 229960002182 imipenem Drugs 0.000 claims description 5
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims description 5
- 229960003786 inosine Drugs 0.000 claims description 5
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 5
- 229960002198 irbesartan Drugs 0.000 claims description 5
- 229950008204 levosalbutamol Drugs 0.000 claims description 5
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 claims description 5
- 229960002525 mecamylamine Drugs 0.000 claims description 5
- KXMTXZACPVCDMH-UHFFFAOYSA-N methyl 4-[5-(hydroxymethyl)-7-methoxy-1,3-benzodioxol-4-yl]-7-methoxy-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1CO KXMTXZACPVCDMH-UHFFFAOYSA-N 0.000 claims description 5
- 229960001782 methyldopate Drugs 0.000 claims description 5
- 229960003738 meticrane Drugs 0.000 claims description 5
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 claims description 5
- 229960004398 nedocromil Drugs 0.000 claims description 5
- 229960002187 nifenazone Drugs 0.000 claims description 5
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims description 5
- 229960005117 olmesartan Drugs 0.000 claims description 5
- 229960003625 oxolamine Drugs 0.000 claims description 5
- 229960002625 pazufloxacin Drugs 0.000 claims description 5
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 claims description 5
- 229960004236 pefloxacin Drugs 0.000 claims description 5
- 229960000762 perphenazine Drugs 0.000 claims description 5
- 229960002895 phenylbutazone Drugs 0.000 claims description 5
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims description 5
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 claims description 5
- 229960004633 pirenzepine Drugs 0.000 claims description 5
- 229960001085 piretanide Drugs 0.000 claims description 5
- 229950008905 pretomanid Drugs 0.000 claims description 5
- 229960001404 quinidine Drugs 0.000 claims description 5
- 229960004136 rivastigmine Drugs 0.000 claims description 5
- 229960005224 roxithromycin Drugs 0.000 claims description 5
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 claims description 5
- 229960000973 sulfadimethoxine Drugs 0.000 claims description 5
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 claims description 5
- 229950000034 teneligliptin Drugs 0.000 claims description 5
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims description 5
- 229960004659 ticarcillin Drugs 0.000 claims description 5
- 229950001089 todralazine Drugs 0.000 claims description 5
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 5
- 229960001350 tofacitinib Drugs 0.000 claims description 5
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims description 5
- 229960001017 tolmetin Drugs 0.000 claims description 5
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 5
- 229960000401 tranexamic acid Drugs 0.000 claims description 5
- IWYJYHUNXVAVAA-OAHLLOKOSA-N trelagliptin Chemical compound C=1C(F)=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 IWYJYHUNXVAVAA-OAHLLOKOSA-N 0.000 claims description 5
- 229950010728 trelagliptin Drugs 0.000 claims description 5
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 claims description 5
- 229960004813 trichlormethiazide Drugs 0.000 claims description 5
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 claims description 5
- 229960004453 trimethadione Drugs 0.000 claims description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 5
- 229960000281 trometamol Drugs 0.000 claims description 5
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 3
- 238000002648 combination therapy Methods 0.000 claims description 2
- 238000010172 mouse model Methods 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 230000005880 cancer cell killing Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 238000012447 xenograft mouse model Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 238000009511 drug repositioning Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 201000007490 Adenocarcinoma in Situ Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101100490193 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ACL4 gene Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000012418 validation experiment Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Definitions
- This disclosure generally relates to drug repurposing, and especially a list of identified approved drugs as potential anti-tumor agents against lung adenocarcinoma (LUAD) .
- LAD lung adenocarcinoma
- Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths in the world.
- LUAD is a form of non-small cell lung cancer (NSCLC) , which is the most common type of lung cancer. NSCLCs account for 80%of lung malignancies, of which 50%are roughly diagnosed as adenocarcinomas.
- LUAD is usually classified into the following several subtypes: adenocarcinoma in situ (AIS) , minimally invasive adenocarcinoma (MIA) , invasive adenocarcinoma, and variants of adenocarcinoma.
- AIS adenocarcinoma in situ
- MIA minimally invasive adenocarcinoma
- MIA minimally invasive adenocarcinoma
- variants of adenocarcinoma Despite advances in treatment strategies, the 5-year survival for LUAD patients remains low (approximately 20%) worldwide.
- a method of treating lung adenocarcinoma can include administering to a subject in need thereof any one or a combination of at least two of drugs or compounds listed in Table 1: methyldopate, guanethidine, diphenylpyraline, tolmetin, nifenazone, Cephalothin, heptaminol, trichlormethiazide, Bucladesine, acetylcholine, imipenem, roxithromycin, butacaine, rivastigmine, ticarcillin, olmesartan, oxolamine, pirenzepine, sulfadimethoxine, tofacitinib, levalbuterol, mecamylamine, meticrane, phenylbutazone, todralazine, tranexamic acid, trimethadione, hydroquinidine, pazuflox
- the drugs or compounds shown in Table 1 can be administered in a therapeutically effective amount.
- the therapeutically effective amount is sufficient for inhibiting growth of LUAD cells. In some embodiments, the therapeutically effective amount is sufficient for inhibiting LUAD cell proliferation.
- the drugs or compounds shown in Table 1 can be administered orally or via injection.
- the present disclosure provides a method of treating LUAD by administering to a subject in need thereof any one or a combination of at least two of drugs or compounds shown in Table 1, and a convertional anti-LUAD drug (s) .
- the aforementioned drugs lead to a number of low IC50.
- the aforementioned drugs reduce the volume of tumor of cell line derived xenografts (CDX) model.
- the subject is human.
- the LUAD is NSCLC.
- the present disclosure provides any one of the drugs listed in Table 1 for use in treating LUAD.
- the present disclosure further provides use of any one of the drugs listed in Table 1 in treating LUAD.
- the present disclosure further provides a method for treating LUAD in a clinical patient, comprising administering to the patient a clinically relevant dosage range of a drug or compound listed in Table 1.
- the drug or compound is administered at a therapeutically effective concentration.
- the administration of said drug or compound reduces the volume of LUAD tumor in clinical patients.
- the present disclosure further provides a combination therapy to treat a LUAD patient to control the development of tumor, comprising administering a clinical range of a non-anti-LUAD drug proposed to be repurposed with a conventional anti-LUAD drug to the patient, wherein the combination of said non-anti-LUAD drug and said conventional anti-LUAD drug is administered at a clinically relevant dosage.
- said non-anti-LUAD drug provides synergy to said conventional anti-LUAD drug.
- the non-anti-LUAD drug is selected from the group consisting of methyldopate, guanethidine, diphenylpyraline, tolmetin, nifenazone, Cephalothin, heptaminol, trichlormethiazide, Bucladesine, acetylcholine, imipenem, roxithromycin, butacaine, rivastigmine, ticarcillin, olmesartan, oxolamine, pirenzepine, sulfadimethoxine, tofacitinib, levalbuterol, mecamylamine, meticrane, phenylbutazone, todralazine, tranexamic acid, trimethadione, hydroquinidine, pazufloxacin, bretylium, almitrine, chloroprocaine, hydroflumethiazide, deslanoside, Fomepizole, bicyclo
- the present disclosure further provides a pharmaceutical combination comprising any one or a combination of at least two of the drugs listed in Table 1, and a conventional anti-LUAD drug.
- the human LUAD cell lines were sourced from commercial vendors. The cancer cells were cultured in RPMI 1640 Medium, supplemented with 10%FBS and 1%penicillin/streptomycin, and were maintained in an incubator at 37 °C and 5%CO 2 . Then the human LUAD cell lines cells were each plated at 5,000 cells per 100 ⁇ l AR-5 medium (ACL4 media with 5%FBS) per well in 96-well plates. For some of screened drugs with definite IC 50 s in public datasets, cells were treated with them in considerate IC 50 s concentrations. Cells were collected on day 0 (control) or after 48 h of treatment. For others, cells per well were treated with those drugs at their indicated doses as a series of concentrations. After three or five days of treatment cells were collected. The cell viability of the samples was used to assess drugs sensitivity.
- mice Male BALB/c nude mice were housed in a specific pathogen-free facility. In total, 1 ⁇ 10 7 human LUAD cell lines were suspended in PBS and injected subcutaneously into the right flank of each mouse to generate xenograft tumors. When the tumor volume reached an average of ⁇ 100 mm 3 , mice were randomly divided into four groups for each drug: the DMSO group and the drug treated (three different low, medium, and high concentrations of the drug) group; each group had three technical replicate samples. The mice in each group were treated with drug or DMSO through oral gavage or injection. The oral gavage or injection repeated once a day for two weeks. The tumor size (length and width) was measured using a digital caliper every other day to monitor the growth of the tumor. The formula was used to evaluate tumor volume at indicated time points: 1/2 ⁇ L ⁇ W 2 , with L denoting the longest tumor diameter and W is the shortest. Mouse was weighed every other day.
Abstract
A method of treating lung adenocarcinoma (LUAD), a subtype of non-small cell lung cancer (NSCLC), is provided. This method of treating LUAD can include: providing non anti-LUAD drugs or compounds provided herein to a subject having LUAD.
Description
This disclosure generally relates to drug repurposing, and especially a list of identified approved drugs as potential anti-tumor agents against lung adenocarcinoma (LUAD) .
BACKGROUD
Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths in the world. LUAD is a form of non-small cell lung cancer (NSCLC) , which is the most common type of lung cancer. NSCLCs account for 80%of lung malignancies, of which 50%are roughly diagnosed as adenocarcinomas. LUAD is usually classified into the following several subtypes: adenocarcinoma in situ (AIS) , minimally invasive adenocarcinoma (MIA) , invasive adenocarcinoma, and variants of adenocarcinoma. Despite advances in treatment strategies, the 5-year survival for LUAD patients remains low (approximately 20%) worldwide. Nowadays, drug repositioning, repurposing of existing drugs currently used for different indications and the introduction of a different method of drug administration, is considered as an cost-effective and pragmatic way to improve lung cancer therapy. Accordingly, it would be important to accelerate drug discovery and approval by drug repurposing, which can help improve outcomes for patients affected by lung adenocarcinoma.
SUMMARY
In an aspect, a method of treating lung adenocarcinoma (LUAD) is provided. The method of treating LUAD can include administering to a subject in need thereof any one or a combination of at least two of drugs or compounds listed in Table 1: methyldopate, guanethidine, diphenylpyraline, tolmetin, nifenazone, Cephalothin, heptaminol, trichlormethiazide, Bucladesine, acetylcholine, imipenem, roxithromycin, butacaine, rivastigmine, ticarcillin, olmesartan, oxolamine, pirenzepine, sulfadimethoxine, tofacitinib, levalbuterol, mecamylamine, meticrane, phenylbutazone, todralazine, tranexamic acid, trimethadione, hydroquinidine, pazufloxacin, bretylium, almitrine, chloroprocaine, hydroflumethiazide, deslanoside, Fomepizole, bicyclol, pretomanid, nedocromil, irbesartan, riboflavin-5-phosphate, succinic-acid, gallopamil, boceprevir, teneligliptin, trelagliptin, alogliptin, anagliptin, carbenoxolone, dicoumarol, azosemide, piretanide, garenoxacin, pefloxacin, L-citrulline, aprindine, flunarizine, perphenazine, anisindione, quinidine, inosine, Aminocaproic acid, and trometamol.
The drugs or compounds shown in Table 1 can be administered in a therapeutically effective amount. In some embodiments, the therapeutically effective amount is sufficient for inhibiting growth of LUAD cells. In some embodiments, the therapeutically effective amount is sufficient for inhibiting LUAD cell proliferation.
Table 1. Candidate drugs for LUAD treatment.
methyldopate | olmesartan | almitrine | alogliptin |
guanethidine | oxolamine | chloroprocaine | anagliptin |
diphenylpyraline | pirenzepine | hydroflumethiazide | carbenoxolone |
tolmetin | sulfadimethoxine | deslanoside | dicoumarol |
nifenazone | tofacitinib | Fomepizole | azosemide |
Cephalothin | levalbuterol | bicyclol | piretanide |
heptaminol | mecamylamine | pretomanid | garenoxacin |
trichlormethiazide | meticrane | nedocromil | pefloxacin |
Bucladesine | phenylbutazone | irbesartan | L-citrulline |
acetylcholine | todralazine | riboflavin-5-phosphate | aprindine |
imipenem | tranexamic acid | succinic-acid | flunarizine |
roxithromycin | trimethadione | gallopamil | perphenazine |
butacaine | hydroquinidine | boceprevir | anisindione |
rivastigmine | pazufloxacin | teneligliptin | quinidine |
ticarcillin | bretylium | trelagliptin | inosine |
Aminocaproic acid | trometamol |
In some embodiments, the drugs or compounds shown in Table 1 can be administered orally or via injection.
In an aspect, the present disclosure provides a method of treating LUAD by administering to a subject in need thereof any one or a combination of at least two of drugs or compounds shown in Table 1, and a convertional anti-LUAD drug (s) .
In some embodiments, the aforementioned drugs lead to a number of low IC50.
In some embodiments, the aforementioned drugs reduce the volume of tumor of cell line derived xenografts (CDX) model.
In some embodiments, the subject is human.
In some embodiments, the LUAD is NSCLC.
The following descriptions and claims give a better understanding of the invention’s features, aspects and advantages.
The present disclosure provides any one of the drugs listed in Table 1 for use in treating LUAD.
The present disclosure further provides use of any one of the drugs listed in Table 1 in treating LUAD.
The present disclosure further provides a method for treating LUAD in a clinical patient, comprising administering to the patient a clinically relevant dosage range of a drug or compound listed in Table 1.
In an embodiment, the drug or compound is administered at a therapeutically effective concentration.
In an embodiment, the administration of said drug or compound reduces the volume of LUAD tumor in clinical patients.
The present disclosure further provides a combination therapy to treat a LUAD patient to control the development of tumor, comprising administering a clinical range of a non-anti-LUAD drug proposed to be repurposed with a conventional anti-LUAD drug to the patient, wherein the combination of said non-anti-LUAD drug and said conventional anti-LUAD drug is administered at a clinically relevant dosage.
In an embodiment, said non-anti-LUAD drug provides synergy to said conventional anti-LUAD drug.
In an embodiment, the non-anti-LUAD drug is selected from the group consisting of methyldopate, guanethidine, diphenylpyraline, tolmetin, nifenazone, Cephalothin, heptaminol, trichlormethiazide, Bucladesine, acetylcholine, imipenem, roxithromycin, butacaine, rivastigmine, ticarcillin, olmesartan, oxolamine, pirenzepine, sulfadimethoxine, tofacitinib, levalbuterol, mecamylamine, meticrane, phenylbutazone, todralazine, tranexamic acid, trimethadione, hydroquinidine, pazufloxacin, bretylium, almitrine, chloroprocaine, hydroflumethiazide, deslanoside, Fomepizole, bicyclol, pretomanid, nedocromil, irbesartan, riboflavin-5-phosphate, succinic-acid, gallopamil, boceprevir, teneligliptin, trelagliptin, alogliptin, anagliptin, carbenoxolone, dicoumarol, azosemide, piretanide, garenoxacin, pefloxacin, L-citrulline, aprindine, flunarizine, perphenazine, anisindione, quinidine, inosine, Aminocaproic acid, and trometamol.
The present disclosure further provides a pharmaceutical combination comprising any one or a combination of at least two of the drugs listed in Table 1, and a conventional anti-LUAD drug.
Materials and methods
Experiments on lung cancer cell lines
Validation experiments of drug sensitivity on treating NSCLC were conducted. The human LUAD cell lines were sourced from commercial vendors. The cancer cells were cultured in RPMI 1640 Medium, supplemented with 10%FBS and 1%penicillin/streptomycin, and were maintained in an incubator at 37 ℃ and 5%CO
2. Then the human LUAD cell lines cells were each plated at 5,000 cells per 100μl AR-5 medium (ACL4 media with 5%FBS) per well in 96-well plates. For some of screened drugs with definite IC
50s in public datasets, cells were treated with them in considerate IC
50s concentrations. Cells were collected on day 0 (control) or after 48 h of treatment. For others, cells per well were treated with those drugs at their indicated doses as a series of concentrations. After three or five days of treatment cells were collected. The cell viability of the samples was used to assess drugs sensitivity.
Secondly, we did the experiments with 4 groups for each drug: control, three drug concentrations (represent three different low, medium, and high concentrations of the drug) on the human LUAD cell lines. Each group had three technical replicate samples. After 24 hours, all the samples were used to do the RNA-Seq experiments and the downstream analysis.
Animal model experiments
Male BALB/c nude mice were housed in a specific pathogen-free facility. In total, 1×10
7 human LUAD cell lines were suspended in PBS and injected subcutaneously into the right flank of each mouse to generate xenograft tumors. When the tumor volume reached an average of ~ 100 mm
3, mice were randomly divided into four groups for each drug: the DMSO group and the drug treated (three different low, medium, and high concentrations of the drug) group; each group had three technical replicate samples. The mice in each group were treated with drug or DMSO through oral gavage or injection. The oral gavage or injection repeated once a day for two weeks. The tumor size (length and width) was measured using a digital caliper every other day to monitor the growth of the tumor. The formula was used to evaluate tumor volume at indicated time points: 1/2×L×W
2, with L denoting the longest tumor diameter and W is the shortest. Mouse was weighed every other day.
Claims (9)
- A method of using candidate drugs/compounds to treat lung adenocarcinoma (LUAD) , comprising:a) screening a list of drugs/compounds, wherein the list includes a plurality of approved drugs or compounds which have not been used against LUAD to date of this disclosure;b) identifying several drugs/compounds from the list for their ability to reduce tumor volume, perform cancer cell killing or inhibit tumor growth in mouse model with not strongly interfering normal physiology function and little side effects;c) the purpose and application of identified candidate drugs/compounds on LUAD treatment;d) the concentration/dose of identified candidate drugs/compounds used in clinical settings.
- The method according to claim 1, wherein the mouse model and tumor specifically refers to LUAD cancer model and LUAD tumor respectively; wherein mouse models of cancer refers to mouse xenograft models (cell line derived xenografts (CDX) model) .
- The method of according to claim 1, wherein the dosage of drugs/compounds used in clinical is dependent on clinical experiments.
- A method of treating LUAD in a clinical patient, comprising administering to the patient a clinical relevant dosage range of a drug or compound, wherein the drug or compound is any one or a combination of at least two selected from the group consisting of methyldopate, guanethidine, diphenylpyraline, tolmetin, nifenazone, Cephalothin, heptaminol, trichlormethiazide, Bucladesine, acetylcholine, imipenem, roxithromycin, butacaine, rivastigmine, ticarcillin, olmesartan, oxolamine, pirenzepine, sulfadimethoxine, tofacitinib, levalbuterol, mecamylamine, meticrane, phenylbutazone, todralazine, tranexamic acid, trimethadione, hydroquinidine, pazufloxacin, bretylium, almitrine, chloroprocaine, hydroflumethiazide, deslanoside, Fomepizole, bicyclol, pretomanid, nedocromil, irbesartan, riboflavin-5-phosphate, succinic-acid, gallopamil, boceprevir, teneligliptin, trelagliptin, alogliptin, anagliptin, carbenoxolone, dicoumarol, azosemide, piretanide, garenoxacin, pefloxacin, L-citrulline, aprindine, flunarizine, perphenazine, anisindione, quinidine, inosine, Aminocaproic acid, and trometamol.
- The method of claim 4, wherein said clinically relevant dosage range is about micromolar to about nanomolar.
- The method of claim 4, wherein the administration of said drug or compound reduces the volume of LUAD tumor in clinical patients.
- A combination therapy to treat a LUAD patient to control the development of tumor, comprising administering a clinical range of a non-anti-LUAD drug proposed to be repurposed with a conventional anti-LUAD drug to the patient, wherein the combination of said non-anti-LUAD drug and said conventional anti-LUAD drug is administered at a clinically relevant dosage.
- The combinational therapy according to claim 7, wherein said non-anti-LUAD drug provides synergy to said conventional anti-LUAD drug.
- The combinational therapy according to claim 7, wherein the non-anti-LUAD drug is selected from the group consisting of methyldopate, guanethidine, diphenylpyraline, tolmetin, nifenazone, Cephalothin, heptaminol, trichlormethiazide, Bucladesine, acetylcholine, imipenem, roxithromycin, butacaine, rivastigmine, ticarcillin, olmesartan, oxolamine, pirenzepine, sulfadimethoxine, tofacitinib, levalbuterol, mecamylamine, meticrane, phenylbutazone, todralazine, tranexamic acid, trimethadione, hydroquinidine, pazufloxacin, bretylium, almitrine, chloroprocaine, hydroflumethiazide, deslanoside, Fomepizole, bicyclol, pretomanid, nedocromil, irbesartan, riboflavin-5-phosphate, succinic-acid, gallopamil, boceprevir, teneligliptin, trelagliptin, alogliptin, anagliptin, carbenoxolone, dicoumarol, azosemide, piretanide, garenoxacin, pefloxacin, L-citrulline, aprindine, flunarizine, perphenazine, anisindione, quinidine, inosine, Aminocaproic acid, and trometamol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2022/096011 WO2023230770A1 (en) | 2022-05-30 | 2022-05-30 | Methods of lung adenocarcinoma treatment with non anti-luad drugs or compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2022/096011 WO2023230770A1 (en) | 2022-05-30 | 2022-05-30 | Methods of lung adenocarcinoma treatment with non anti-luad drugs or compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023230770A1 true WO2023230770A1 (en) | 2023-12-07 |
Family
ID=89026490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/096011 WO2023230770A1 (en) | 2022-05-30 | 2022-05-30 | Methods of lung adenocarcinoma treatment with non anti-luad drugs or compounds |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023230770A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104703600A (en) * | 2012-09-07 | 2015-06-10 | 埃克塞里艾克西斯公司 | Inhibitors of MET, VEGFR and RET for use in the treatment of lung adenocarcinoma |
US20160018399A1 (en) * | 2013-03-08 | 2016-01-21 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation |
WO2017201142A1 (en) * | 2016-05-17 | 2017-11-23 | Memorial Sloan Kettering Cancer Center | Treatment of lung adenocarcinoma |
US20190117596A1 (en) * | 2016-04-29 | 2019-04-25 | Wayne State University | Ty-52156 compounds for the treatment of cancer |
US20210023066A1 (en) * | 2016-09-20 | 2021-01-28 | Children's Hospital Medical Center | Compositions and methods for treatment of cancer |
CN113512531A (en) * | 2021-06-04 | 2021-10-19 | 广东省实验动物监测所 | Lung adenocarcinoma cell line and application thereof |
-
2022
- 2022-05-30 WO PCT/CN2022/096011 patent/WO2023230770A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104703600A (en) * | 2012-09-07 | 2015-06-10 | 埃克塞里艾克西斯公司 | Inhibitors of MET, VEGFR and RET for use in the treatment of lung adenocarcinoma |
US20160018399A1 (en) * | 2013-03-08 | 2016-01-21 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating mammals having lung adenocarcinoma characterized by neuroendocrine differentiation |
US20190117596A1 (en) * | 2016-04-29 | 2019-04-25 | Wayne State University | Ty-52156 compounds for the treatment of cancer |
WO2017201142A1 (en) * | 2016-05-17 | 2017-11-23 | Memorial Sloan Kettering Cancer Center | Treatment of lung adenocarcinoma |
US20210023066A1 (en) * | 2016-09-20 | 2021-01-28 | Children's Hospital Medical Center | Compositions and methods for treatment of cancer |
CN113512531A (en) * | 2021-06-04 | 2021-10-19 | 广东省实验动物监测所 | Lung adenocarcinoma cell line and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Miousse et al. | Effects of ionizing radiation on DNA methylation: from experimental biology to clinical applications | |
Chang et al. | Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O6-methylguanine-DNA methyltransferase | |
Feng et al. | MiR-124 inhibits cell proliferation in breast cancer through downregulation of CDK4 | |
CN105263523A (en) | Combination cancer treatments utilizing micro RNA and EGFR-TKI inhibitors | |
Bian et al. | Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner | |
Hashemi et al. | Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions | |
TW201943428A (en) | Method for preventing or treating side effects of cancer therapy | |
EP4013869A1 (en) | New treatments involving mirna-193a | |
CN111956804B (en) | Novel use of inhibitors of OTUB1 | |
EP3442505A1 (en) | Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors | |
JP2017519006A (en) | Stimulation of cancer cells by low-dose naltrexone | |
Tian et al. | Inhibition of glycolysis by a novel EGFR/HER2 inhibitor KU004 suppresses the growth of HER2+ cancer | |
WO2004050837A2 (en) | Treatment of dna damage related disorders | |
WO2023230770A1 (en) | Methods of lung adenocarcinoma treatment with non anti-luad drugs or compounds | |
CN111714480A (en) | Use of anthranilic acid derivatives in the manufacture of a medicament for the treatment of cancer | |
US20100016421A1 (en) | Methods for determining sensitivity to aminoflavones | |
Rafiei et al. | Gene expression of angiogenesis and apoptotic factors in female BALB/c mice with breast cancer after eight weeks of aerobic training | |
US20090131391A1 (en) | Inhibitor for differentiation of hematopoietic precursor cells | |
CN111494385A (en) | Medicine for treating ovarian cancer and preparation method and application thereof | |
WO2022252044A1 (en) | Drug repurposing to treat primary lung adenocarcinoma based on deep embeddings of single-cell sequencing analysis | |
US20130059906A1 (en) | Methods and compositions for influencing tumors using microrna-185 as a tumor suppressor | |
Levashov et al. | MEDU-12. TREATMENT RESULTS OF CHILDREN WITH METASTATIC MEDULLOBLASTOMA ACCORDING TO C-MYC/N-MYC/Iso17q AND MGMT TUMOR STATUS | |
US11827588B2 (en) | Compound, agent and composition for the suppression of cancer growth | |
CN110279704B (en) | Adriamycin combined medicine and application thereof | |
KR20030071029A (en) | Composition useful as anticancer drug and radiosensitizer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22944112 Country of ref document: EP Kind code of ref document: A1 |